What is biotherapy? The monoclonal antibody case;Qu'est-ce qu'une biothérapie ? L'exemple des anticorps monoclonaux

Presse Medicale

Volumn 38, Issue 5, 2009, Pages 825-831

  Teillaud, Jean Luc ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; CAPROMAB PENDETIDE IN 111; CETUXIMAB; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; OFATUMUMAB; OKT 3; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; RANIBIZUMAB; RITUXIMAB; TRASTUZUMAB; ZANOLIMUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ALLERGIC ASTHMA; AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; CANCER SCINTISCANNING; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; CROHN DISEASE; CUTANEOUS T CELL LYMPHOMA; DRUG INDICATION; GRAFT REJECTION; HEMATOLOGIC DISEASE; HUMAN; METASTASIS; MULTIPLE SCLEROSIS; NEOPLASM; NONHODGKIN LYMPHOMA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; POSTOPERATIVE THROMBOSIS; PROSTATE CANCER; PSORIASIS; RETINA MACULA AGE RELATED DEGENERATION; RHEUMATOID ARTHRITIS; SHORT SURVEY; VIRAL RESPIRATORY TRACT INFECTION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CELL MIGRATION INHIBITION; EVOLUTION, MOLECULAR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RESPIRATORY SYNCYTIAL VIRUSES; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 65449135581     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2008.12.025     Document Type: Short Survey

References (17)

1. Köhler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (1975) 495-497
2. Miller R.A., Maloney D.G., Warnke R., and Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306 (1982) 517-522
3. Boulianne G.L., Hozumi N., and Shulman M.J. Production of functional chimaeric mouse/human antibody. Nature 312 (1984) 643-646
4. Morrison S.L., Johnson M.J., Herzenberg L.A., and Oi V.T. Chimeric human antibody molecules : mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 81 (1984) 6851-6855
5. Jones P.T., Dear P.H., Foote J., Neuberger M.S., and Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321 (1986) 522-525
6. Roguska M.A., Pedersen J.T., Keddy C.A., Henry A.H., Searle S.J., Lambert J.M., et al. Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc Natl Acad Sci USA 91 (1994) 969-973
7. McCafferty J., Griffiths A.D., Winter G., and Chiswell D.J. Phage antibodies : filamentous phage displaying antibody variable domains. Nature 348 (1990) 552-554
8. Green L.L., Hardy M.C., Maynard-Currie C.E., Tsuda H., Louie D.M., Mendez M.J., et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet 7 (1994) 13-21
9. Lonberg N., Taylor L.D., Harding F.A., Trounstine M., Higgins K.M., Schramm S.R., et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368 (1994) 856-859
10. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99 (2002) 754-758
11. Shields R.L., Namenuk A.K., Hong K., Meng Y.G., Rae J., Briggs J., et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the Fcgamma R. J Biol Chem 276 (2001) 6591-6604
12. Umana P., Jean-Mairet J., Moudry R., Amstutz H., and Bailey J.E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17 (1999) 176-180
13. Shinkawa T., Nakamura K., Yamane N., Shoji-Hosaka E., Kanda Y., Sakurada M., et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278 (2003) 3466-3473
14. Sibéril S., de Romeuf C., Bihoreau N., Fernandez N., Meterreau J.L., Regenman A., et al. Selection of a human anti-RhD monoclonal antibody for therapeutic use : impact of IgG glycosylation on activating and inhibitory FcγR functions. Clin Immunol 118 (2006) 170-179
15. Béliard R., Waegemans T., Notelet D., Massad L., Dhainaut F., de Romeuf C., et al. An anti-D monoclonal antibody selected for enhanced FcγRIII engagement clears RhD-positive autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies. British J Haematol 141 (2008) 109-119
16. de Romeuf C., Dutertre C.A., Le Garff-Tavernier M., Fournier N., Gaucher C., Glacet A., et al. CLL cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16. British J Hæmatol 140 (2008) 635-643
17. Teeling J.L., French R.R., Cragg M.S., van den Brakel J., Pluyter M., Huang H., et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104 (2004) 1793-1800